明星基金经理二季度调仓曝光

Core Viewpoint - The article highlights the ongoing strong performance of the innovative drug sector, with several prominent fund managers increasing their allocations to this area in the second quarter of 2025, indicating a positive outlook for the sector's continuation despite potential adjustments and volatility ahead [2][3][12]. Group 1: Fund Manager Insights - Fund managers such as Fu Pengbo and Gao Nan have notably increased their investments in the pharmaceutical sector, particularly in innovative drugs, amidst a favorable market environment [2][4]. - Fu Pengbo's fund, Ruiyuan Growth Value, maintained a high allocation with over 92% in stock assets, focusing on sectors like electronics, internet technology, precision manufacturing, and pharmaceuticals [6][7]. - Gao Nan's management of multiple funds saw a nearly 30% increase in total assets under management, with a focus on TMT, innovative drugs, and new consumption sectors [9][10]. Group 2: Market Trends and Future Outlook - The innovative drug sector is viewed as a necessary evolution rather than an option, with the potential for significant growth driven by companies with strong technological capabilities [11][13]. - The article notes that the current phase of the innovative drug industry is akin to the explosive growth seen in the CXO sector from 2018 to 2019, suggesting a similar trajectory for future developments [13]. - Key trends to watch in the third quarter include overseas licensing of drug pipelines and domestic sales growth, contingent on quarterly reports and negotiations with insurance providers [14].